vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and P10, Inc. (PX). Click either name above to swap in a different company.

P10, Inc. is the larger business by last-quarter revenue ($81.0M vs $48.0M, roughly 1.7× BICYCLE THERAPEUTICS PLC). P10, Inc. runs the higher net margin — 11.7% vs -42.0%, a 53.7% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -4.7%). P10, Inc. produced more free cash flow last quarter ($18.1M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 10.7%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.

BCYC vs PX — Head-to-Head

Bigger by revenue
PX
PX
1.7× larger
PX
$81.0M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1198.0% gap
BCYC
1193.3%
-4.7%
PX
Higher net margin
PX
PX
53.7% more per $
PX
11.7%
-42.0%
BCYC
More free cash flow
PX
PX
$38.0M more FCF
PX
$18.1M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
10.7%
PX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
PX
PX
Revenue
$48.0M
$81.0M
Net Profit
$-20.2M
$9.5M
Gross Margin
Operating Margin
-51.5%
31.9%
Net Margin
-42.0%
11.7%
Revenue YoY
1193.3%
-4.7%
Net Profit YoY
61.1%
79.0%
EPS (diluted)
$-0.29
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
PX
PX
Q4 25
$48.0M
$81.0M
Q3 25
$11.7M
$75.9M
Q2 25
$2.9M
$72.7M
Q1 25
$10.0M
$67.7M
Q4 24
$3.7M
$85.0M
Q3 24
$2.7M
$74.2M
Q2 24
$9.4M
$71.1M
Q1 24
$19.5M
$66.1M
Net Profit
BCYC
BCYC
PX
PX
Q4 25
$-20.2M
$9.5M
Q3 25
$-59.1M
$2.1M
Q2 25
$-79.0M
$3.4M
Q1 25
$-60.8M
$4.5M
Q4 24
$5.3M
Q3 24
$-50.8M
$1.4M
Q2 24
$-39.8M
$7.0M
Q1 24
$-26.6M
$5.0M
Operating Margin
BCYC
BCYC
PX
PX
Q4 25
-51.5%
31.9%
Q3 25
-558.6%
14.1%
Q2 25
-2965.8%
24.4%
Q1 25
-703.7%
16.6%
Q4 24
26.9%
Q3 24
-2385.9%
11.9%
Q2 24
-498.3%
23.7%
Q1 24
-162.4%
18.3%
Net Margin
BCYC
BCYC
PX
PX
Q4 25
-42.0%
11.7%
Q3 25
-503.7%
2.8%
Q2 25
-2703.8%
4.7%
Q1 25
-608.9%
6.7%
Q4 24
6.2%
Q3 24
-1898.4%
1.9%
Q2 24
-425.3%
9.8%
Q1 24
-136.0%
7.6%
EPS (diluted)
BCYC
BCYC
PX
PX
Q4 25
$-0.29
$0.08
Q3 25
$-0.85
$0.02
Q2 25
$-1.14
$0.03
Q1 25
$-0.88
$0.04
Q4 24
$0.05
Q3 24
$-0.74
$0.01
Q2 24
$-0.77
$0.06
Q1 24
$-0.62
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
PX
PX
Cash + ST InvestmentsLiquidity on hand
$628.1M
$28.2M
Total DebtLower is stronger
$373.2M
Stockholders' EquityBook value
$610.0M
$403.5M
Total Assets
$717.6M
$928.3M
Debt / EquityLower = less leverage
0.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
PX
PX
Q4 25
$628.1M
$28.2M
Q3 25
$648.3M
$40.0M
Q2 25
$721.5M
$33.4M
Q1 25
$793.0M
$74.4M
Q4 24
$879.5M
$67.5M
Q3 24
$890.9M
$61.5M
Q2 24
$961.4M
$31.2M
Q1 24
$457.0M
$29.0M
Total Debt
BCYC
BCYC
PX
PX
Q4 25
$373.2M
Q3 25
$393.4M
Q2 25
$373.0M
Q1 25
$357.2M
Q4 24
$319.8M
Q3 24
$319.4M
Q2 24
$30.9M
$300.6M
Q1 24
$30.8M
$314.0M
Stockholders' Equity
BCYC
BCYC
PX
PX
Q4 25
$610.0M
$403.5M
Q3 25
$618.5M
$396.8M
Q2 25
$668.9M
$388.9M
Q1 25
$740.3M
$374.3M
Q4 24
$793.1M
$386.9M
Q3 24
$831.0M
$394.1M
Q2 24
$873.8M
$396.9M
Q1 24
$356.0M
$400.1M
Total Assets
BCYC
BCYC
PX
PX
Q4 25
$717.6M
$928.3M
Q3 25
$764.0M
$936.0M
Q2 25
$832.2M
$932.2M
Q1 25
$883.9M
$877.4M
Q4 24
$956.9M
$869.3M
Q3 24
$996.7M
$857.0M
Q2 24
$1.1B
$823.2M
Q1 24
$547.1M
$832.8M
Debt / Equity
BCYC
BCYC
PX
PX
Q4 25
0.93×
Q3 25
0.99×
Q2 25
0.96×
Q1 25
0.95×
Q4 24
0.83×
Q3 24
0.81×
Q2 24
0.04×
0.76×
Q1 24
0.09×
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
PX
PX
Operating Cash FlowLast quarter
$-19.3M
$23.0M
Free Cash FlowOCF − Capex
$-19.9M
$18.1M
FCF MarginFCF / Revenue
-41.5%
22.3%
Capex IntensityCapex / Revenue
1.2%
6.0%
Cash ConversionOCF / Net Profit
2.43×
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$14.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
PX
PX
Q4 25
$-19.3M
$23.0M
Q3 25
$-71.2M
$-8.6M
Q2 25
$-72.8M
$13.4M
Q1 25
$-86.4M
$-4.7M
Q4 24
$-164.7M
$101.0M
Q3 24
$-39.8M
$27.5M
Q2 24
$-44.6M
$34.8M
Q1 24
$-70.9M
$11.0M
Free Cash Flow
BCYC
BCYC
PX
PX
Q4 25
$-19.9M
$18.1M
Q3 25
$-71.8M
$-9.5M
Q2 25
$-73.3M
$11.6M
Q1 25
$-87.0M
$-6.0M
Q4 24
$-166.0M
$96.6M
Q3 24
$-40.3M
$25.2M
Q2 24
$-45.0M
$33.9M
Q1 24
$-70.9M
$10.7M
FCF Margin
BCYC
BCYC
PX
PX
Q4 25
-41.5%
22.3%
Q3 25
-612.3%
-12.6%
Q2 25
-2509.7%
15.9%
Q1 25
-871.7%
-8.9%
Q4 24
-4475.7%
113.6%
Q3 24
-1504.7%
34.0%
Q2 24
-481.2%
47.7%
Q1 24
-362.9%
16.2%
Capex Intensity
BCYC
BCYC
PX
PX
Q4 25
1.2%
6.0%
Q3 25
5.7%
1.2%
Q2 25
17.1%
2.5%
Q1 25
6.1%
1.9%
Q4 24
33.3%
5.2%
Q3 24
16.3%
3.0%
Q2 24
4.5%
1.3%
Q1 24
0.1%
0.4%
Cash Conversion
BCYC
BCYC
PX
PX
Q4 25
2.43×
Q3 25
-4.01×
Q2 25
3.96×
Q1 25
-1.05×
Q4 24
19.12×
Q3 24
19.54×
Q2 24
4.98×
Q1 24
2.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCYC
BCYC

Segment breakdown not available.

PX
PX

Management Fees$78.1M96%
Advisory Fees$1.8M2%

Related Comparisons